Most Recent
The plaintiffs in The Cosmetic Institute class action over allegedly botched breast implants will argue a former director of the company was the mastermind behind the ‘one size fits all’ business model, after the business went into liquidation and stopped participating in litigation.
A judge has warned the parties in The Cosmetic Institute class action over allegedly botched breast implants to ensure group members’ rights are prioritised, following a push for an early class closure amid doctor-patient confidentiality concerns.
US biotechnology firm Regeneron Pharmaceuticals has lost its opposition to a proposed patent by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.
A six-week trial set to start in October in the cartel case against mobility equipment provider Country Care Group has been vacated and rescheduled to next year, as the judge overseeing the case quipped that he was either the "canary or the guinea pig" in the landmark criminal proceeding.
Korean drug company Samsung Bioepis has filed a lawsuit seeking to invalidate German drug company Fresenius Kadi's patent for a biosimilar of blockbuster arthritis drug Humira.
A judge has ordered a leading doctor’s professional body to hand over its member list to the applicants in the Ethicon pelvic mesh class action, after the organisation tried to argue its physical member book didn’t strictly fall within the terms of a court order.
Mylan and Cipla have reached a speedy resolution of a consumer lawsuit accusing Cipla of copying the get-up of Mylan's blockbuster cholesterol drug Lipidil.
A judge has slapped a $10 million fine on online supplement company Peptide Clinics for advertising prescription-only drugs in breach of the Therapeutic Goods Act.
Mylan has launched a lawsuit against Cipla for allegedly copying the get-up of its blockbuster cholesterol drug Lipidil, after losing a bid to block Cipla and Sun Pharma from selling generic versions of the drug while it appeals a ruling invalidating several claims of its patents.
A unit of Boehringer Ingelheim has been given more time to oppose a proposed patent by rival drug maker Intervet, after the German drug company's lawyers sent an email with the wrong opposition deadline.